证券代码：002932 证券简称：明德生物 武汉明德生物科技股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券-郭梁良，偕沣资产-裴管铖，南土资产-许智涵 | | 人员姓名 | | | | 时间 | 2018 年 9 月 17 | 日下午 14:30-15:30 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董秘-周云、证券事务代表-刘光辉 | | | 员姓名 | | | | 投资者关系活动 | 1 、公司基本情况介绍 | | | 主 ...

武汉明德生物科技股份有限公司 2022 年第三季度报告 证券代码：002932 证券简称：明德生物 公告编号：2022-091 武汉明德生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季度报告中财务信息的真实、准 确、完整。 3、第三季度报告未经过审计。 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 2,216,728,872.20 | 178.14% | 7,469,957,203.91 | 285.38 ...

武汉明德生物科技股份有限公司 2022 年半年度报告全文 武汉明德生物科技股份有限公司 2022 年半年度报告 2022-054 2022 年 8 月 25 日 1 武汉明德生物科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人陈莉莉、主管会计工作负责人周国辉及会计机构负责人(会计 主管人员)黎朝辉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述，不构成公司对投资者的实 质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 公司在本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分详细描述了未来将面临的主要风险及应对措施，敬请广大投 资者认真阅读相关具体内容，注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以股权登记日总股本为 基数，向全体股东每 10 股派发 ...

证券代码：002932 证券简称：明德生物 公告编号：2022-042 武汉明德生物科技股份有限公司 关于参加 2022 年度湖北辖区上市公司投资者网上集体接待日暨 2021 年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、会议召开时间：2022 年 6 月 16 日（星期四）13：00-16：00 2、会议召开方式：网络方式 一、活动安排 为进一步加强武汉明德生物科技股份有限公司（以下简称"公司"）与投资 者互动交流，公司将于 2022 年 6 月 16 日参加由湖北证监局主办的"2022 年湖 北辖区上市公司投资者集体接待日暨 2021 年度业绩说明会活动"，届时将通过 网络远程的方式与广大投资者就公司发展战略、经营状况、公司治理等投资者关 注的问题进行交流与沟通。 二、召开的时间、方式 召开时间：2022 年 6 月 16 日（星期四）13：00-16：00 会议方式：网络远程形式，通过"全景网"（http://ir.p5w.net/company） 召开本次说明会活动。 三、参加人员 公司副总经理、董事会秘书王 ...

Financial Performance - The company's revenue for Q1 2022 reached ¥2,487,211,050.62, representing a 267.41% increase compared to ¥676,957,006.69 in the same period last year[4] - Net profit attributable to shareholders was ¥1,389,036,851.52, up 307.05% from ¥341,245,407.08 year-over-year[4] - The basic earnings per share increased to ¥13.51, a rise of 281.64% from ¥3.54 in the previous year[4] - Operating profit for Q1 2022 was ¥1,696,790,796.64, compared to ¥417,001,958.88 in Q1 2021, indicating an increase of about 307%[30] - Net profit for Q1 2022 amounted to ¥1,429,474,851.58, up from ¥349,777,380.80 in Q1 2021, reflecting a growth of approximately 309%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,275,986,998.26, reflecting a 54.40% increase from ¥3,417,089,810.18 at the end of the previous year[4] - Total liabilities increased to ¥964,225,895.63 in Q1 2022 from ¥567,016,220.34 in Q1 2021, which is an increase of approximately 70%[28] - The company's total non-current assets reached ¥486,762,509.93 in Q1 2022, compared to ¥417,010,521.76 in the previous year, reflecting an increase of about 16.6%[28] Cash Flow - Cash flow from operating activities was ¥289,745,937.37, an increase of 14.50% compared to ¥253,046,510.68 in the same period last year[4] - The cash flow from operating activities for Q1 2022 was ¥1,484,673,582.69, compared to ¥591,763,328.64 in the same period last year, indicating a growth of about 151%[33] - The total cash and cash equivalents at the end of Q1 2022 reached CNY 1,465,194,076.98, up from CNY 670,763,146.29 at the end of Q1 2021, marking an increase of approximately 118.5%[35] Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,118[12] - The largest shareholder, Chen Lili, holds 27.02% of shares, amounting to 28,340,568 shares, with 21,255,426 shares pledged[12] - The second-largest shareholder, Wang Ying, holds 15.43% of shares, totaling 16,178,058 shares[12] - Chen Lili and Wang Ying are identified as acting in concert, indicating a strategic alignment among major shareholders[13] Research and Development - Research and development expenses grew by 28.16% to ¥28,800,168.74, reflecting an increase in R&D personnel and projects[10] - The company is focused on expanding its product offerings in the medical technology sector, with ongoing research and development efforts[14] - The company is investing in research and development to enhance the accuracy and efficiency of its testing kits, which is expected to improve market competitiveness[15] Product Portfolio and Market Strategy - The company has a diverse portfolio of medical devices, including both Class I and Class II products, enhancing its market position[14] - The company aims to increase its market share through strategic partnerships and collaborations within the healthcare sector[15] - The company is exploring opportunities for mergers and acquisitions to bolster its product portfolio and expand its market presence[15] - The company is strategically positioned to benefit from increasing healthcare needs and advancements in medical technology[19] Product Registrations and Compliance - The company has received registration for multiple medical devices, including the QFT9000 dry fluorescence immunoassay analyzer approved on June 19, 2020, valid until June 18, 2025[14] - The company has a total of 28 registered medical devices, with various approval dates and validity periods[14] - The company has maintained a strong regulatory compliance track record, with all products meeting necessary classification standards[15] - The company is focused on maintaining compliance with regulatory standards to ensure the timely approval of its medical devices[21] Future Outlook - The company anticipates steady growth in revenue driven by the increasing demand for diagnostic testing solutions[15] - The company plans to continue investing in research and development to innovate and improve its product offerings[19] - The ongoing development of new testing kits is expected to drive future revenue growth and market expansion[19]

武汉明德生物科技股份有限公司 2021 年年度报告全文 武汉明德生物科技股份有限公司 2021 年年度报告 2022 年 04 月 1 武汉明德生物科技股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人陈莉莉、主管会计工作负责人周国辉及会计机构负责人（会计 主管人员）黎朝辉声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以股权登记日总股本为基 数，向全体股东每 10 股派发现金红利 30.00 元（含税），送红股 0 股（含税）， 以资本公积金向全体股东每 10 股转增 4.9 股，分派转增比例不变。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 7 | | 第三节 | 管理层讨论与分析 11 | | 第四节 | 公司治理 63 | | 第五节 | 环境和社会责任 85 ...

武汉明德生物科技股份有限公司 2021 年第三季度报告 武汉明德生物科技股份有限公司 2021 年第三季度报告 2021 年 10 月 1 武汉明德生物科技股份有限公司 2021 年第三季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈莉莉、主管会计工作负责人周国辉及会计机构负责人（会计 主管人员） 黎朝辉声明：保证季度报告中财务报表的真实、准确、完整。 2 武汉明德生物科技股份有限公司 2021 年第三季度报告 第二节 公司基本情况 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 同期增减 | | 营业收入（元） | 796,969,010.01 | 185.03% | 1,938,31 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥1,141,344,037.65, representing a 216.55% increase compared to ¥360,562,960.26 in the same period last year[18]. - Net profit attributable to shareholders was ¥579,559,974.59, up 189.53% from ¥200,169,476.57 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥576,812,582.92, reflecting a 187.20% increase compared to ¥200,838,380.59 in the previous year[18]. - The company's cash flow from operating activities was ¥342,718,149.09, an increase of 111.19% from ¥162,283,301.77 in the same period last year[18]. - Basic earnings per share rose to ¥6.17, a 186.98% increase from ¥2.15 in the previous year[18]. - Total assets at the end of the reporting period were ¥2,000,267,741.27, a 40.21% increase from ¥1,426,645,523.77 at the end of the previous year[18]. - Net assets attributable to shareholders increased by 56.08% to ¥1,719,672,588.77 from ¥1,101,793,294.20 at the end of the previous year[18]. - The company achieved a revenue of 1,141.34 million CNY in the first half of 2021, representing a growth of 216.55% year-on-year[46]. - The total profit reached 701.53 million CNY, an increase of 194.93% compared to the same period last year[46]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a year-over-year growth of 25%[99]. Product Development and Innovation - The company has a focus on developing new technologies and products in the biomedical field[11]. - The company has developed a fully automated nucleic acid workstation, enhancing efficiency and reducing contamination risks in testing processes[29]. - The company has developed new COVID-19 antigen and antibody testing reagents, with the antibody test receiving EU CE certification in April 2020 and the antigen test in November 2020[34]. - The company is actively pursuing market expansion with a focus on innovative products, as evidenced by the introduction of multiple new test kits in 2021[97]. - The company is focusing on enhancing product R&D innovation and expanding domestic and international marketing efforts[46]. - The company is strategically positioned to capture market share in the medical testing sector through continuous innovation and product development[1]. - The company has launched multiple COVID-19 related products, including the SARS-CoV-2 Neutralizing Antibody Test Kit and various antigen test kits, enhancing its product portfolio significantly[102]. - The company is developing a new nucleic acid extraction kit, classified as Class I, approved on May 14, 2020, which supports its research and development efforts in molecular diagnostics[97]. - The company has received CE certification for several COVID-19 related test kits, enhancing its market competitiveness in the diagnostics sector[101]. Market Position and Competition - The company achieved operating revenue of 1,141.34 million CNY and a net profit attributable to shareholders of 579.56 million CNY, establishing itself as a leader in China's in vitro diagnostic industry[92]. - The company's COVID-19 nucleic acid testing products have a market share ranking in the top five nationwide, with approximately 1,500 new hospital users added[93]. - The company is facing increasing competition for high-end technical talent, which could impact ongoing projects if key personnel leave; measures include competitive compensation and employee stock ownership plans to retain talent[140]. - The company emphasizes the importance of technology updates and new product development for maintaining market competitiveness and sustainable growth, while acknowledging risks such as technical difficulties and policy changes that may delay R&D progress[139]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting companies with complementary technologies in the diagnostics field[100]. Research and Development - Research and development expenses totaled 49.23 million yuan, reflecting a 154.33% increase compared to the previous year, with new products launched to enrich the product line[53]. - The company has over 200 R&D personnel, with a focus on building a high-efficiency project management model for rapid conversion of R&D results into production[110]. - The company has launched the domestically unique wet blood gas analyzer PT1000, successfully penetrating the market dominated by imported brands[107]. - The company has developed a comprehensive product line in the IVD field, covering areas such as cardiovascular diseases, infectious diseases, and diabetes[111]. - The company has established a solid product structure advantage with a diverse range of IVD products, including POCT, immunoassay, and molecular diagnostics[111]. Corporate Governance and Compliance - The company has not been penalized for environmental violations and complies with relevant environmental laws[159]. - The company has implemented measures to protect employee rights and provided pandemic-related support, including health supplies and vaccinations[161]. - The company has confirmed that all commitments made during the asset restructuring process have been fulfilled[166]. - The company has maintained compliance with all commitments related to stock circulation and management of shares[166]. - The company has outlined specific conditions under which it will activate its stock price stabilization measures, ensuring transparency and adherence to regulatory requirements[167]. Shareholder Engagement and Dividends - The company reported a cash dividend of 15 RMB per 10 shares (including tax) to all shareholders, with no stock bonus or capital reserve conversion[4]. - The company plans to distribute a cash dividend of RMB 15.00 per share (including tax), totaling approximately RMB 144.73 million, which represents 100% of the distributable profit[149]. - The company organized two investor communication activities in 2021 to maintain transparency and engage with shareholders[160]. Financial Management and Investments - The company has engaged in entrusted financial management with a total amount of 38,000 million CNY, including 18,000 million CNY from self-owned funds and 20,000 million CNY from raised funds[191]. - The company has no overdue amounts or impairment provisions related to entrusted financial management[191]. - The company reported a total external guarantee amount of 3,500 million CNY, with an actual guarantee amount of 3,363 million CNY during the reporting period[188]. - The total approved external guarantee amount at the end of the reporting period was 3,500 million CNY, with a remaining balance of 3,194.85 million CNY[188]. Social Responsibility - The company provided over 100 million testing reagents and conducted testing services for over 1.2 million people during the pandemic[163]. - The company donated 11.11 million CNY worth of nucleic acid testing kits and 2 million CNY to support disaster prevention efforts in Henan[163].

2020 年年度报告 2021-043 2021 年 04 月 1 武汉明德生物科技股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 武汉明德生物科技股份有限公司 2020 年年度报告全文 武汉明德生物科技股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人陈莉莉、主管会计工作负责人周芸及会计机构负责人(会计主管 人员)陈婷婷声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 （一）市场竞争风险。近年来，在中国社会向老龄化发展、人均可支配收 入与人均医疗保健支出持续增加、分级诊疗制度推进、诊断技术不断进步的背 景下，我国 IVD 行业得到了快速发展，已成为医疗市场最活跃并且发展最快的 细分行业之一。快速增长的 IVD 市场，吸引了众多国内外生产企业加入竞争， 行业竞争较为激烈。从竞争环境来看，国际跨国公司在我国 IVD 的高端市场中 利用其产品的先发优势占据相对垄断地位，并且部分跨国公司启动了在华投产 策略，以契合中国市场竞 ...

武汉明德生物科技股份有限公司 2020 年年度报告全文 武汉明德生物科技股份有限公司 2020 年年度报告 2021-043 2021 年 04 月 1 武汉明德生物科技股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人陈莉莉、主管会计工作负责人周芸及会计机构负责人(会计主管 人员)陈婷婷声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 （一）市场竞争风险。近年来，在中国社会向老龄化发展、人均可支配收 入与人均医疗保健支出持续增加、分级诊疗制度推进、诊断技术不断进步的背 景下，我国 IVD 行业得到了快速发展，已成为医疗市场最活跃并且发展最快的 细分行业之一。快速增长的 IVD 市场，吸引了众多国内外生产企业加入竞争， 行业竞争较为激烈。从竞争环境来看，国际跨国公司在我国 IVD 的高端市场中 利用其产品的先发优势占据相对垄断地位，并且部分跨国公司启动了在华投产 策略，以契合中国市场竞 ...